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1. Introduction 
The insulin-like growth factor (IGF) family is organized in a complex regulatory network at 
the cellular and sub-cellular levels. In the human the IGF system has a key physiological role 
in the development of the organism and maintenance of normal cellular function during 
foetal and postnatal life. The IGF system consists of three ligands, IGF-I, IGF-II and Insulin; 
three cell membrane receptors, IGF-I receptor (IGF-IR), insulin receptor (IR), and IGF-II 
receptor (IGF-IIR); six high-affinity IGF binding proteins, IGFBP-1 through -6, their specific 
proteases (IGFBP proteases) and membrane receptors (IGFBP-R) (Fig. 1).  
IGF-I and IGF-II share a 62% homology in amino acid sequence and there is a 40% homology 
between the IGFs and proinsulin (Furstenberger & Senn, 2002). IGF-IR is a member of the 
family of the tyrosine kinase growth factor receptors and is highly homologous at the amino 
acid sequence level to the IR. The mature membrane receptor is a tetramer made of two ┙-
chains and two ┚-chains, with several disulfide bridges (LeRoith et al., 1995). The extracellular 
┙-subunits form the ligand binding domain and several lines of evidence suggest that the 
binding sites for IGF-I and IGF-II may be distinct (Samani et al., 2007). IGF-I and IGF-II bind to 
IGF-IR with high affinity, however, ligand affinities may vary with cell type and experimental 
conditions. IGF-II can also bind to the insulin receptor isoform A (IR-A) with an affinity similar 
to that of insulin. IR-A is expressed in certain tumours and has a more mitogenic effect than 
the IR-B isoform, the latter having a more metabolic function (Pandini et al., 2002). In cells 
expressing both IR and IGF-IR, IR hemireceptors may heterodimerize with IGF-IR 
hemireceptors, leading to the formation of hybrid receptors (IR/IGF-IR). The proportion of 
hybrid receptors is a function of the mole fractions of each receptor. Early studies carried out 
with purified hybrid receptors indicate that these receptors mostly bind IGF-I and that they 
bind insulin with a much lower affinity (Belfiore et al., 2009).  
IGF-II can also bind to a second receptor, IGF-IIR, which is a multifunctional single 
transmembrane glycoprotein, identical to the cation-independent mannose 6-phosphate 
receptor. It is composed of a large extracytoplasmic domain and a short cytoplasmic tail that 
lacks intrinsic cytoplasmic activity (El-Shewy & Luttrell, 2009). IGF-IIR perform diverse  
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Fig. 1. The IGF system. The IGF system consists of the receptors (IR, IGF-IR, IGF-IR/IR hybrids 
and IGF-IIR), the peptides (IGF-I, IGF-II and insulin), six high affinity IGFBPs (-1 to -6), IGFBP 
proteases and IGFBP receptors (IGFBP-R).  
cellular functions related to lysosome biogenesis and the regulation of growth and 
development. The IGF-IIR receptors recycle continuosly between two cellular pools and at 
steady state most of the receptor localize in endosomes and the remainder (approx. 10%) on 
the plasma membrane. Traditionally, the IGF-IIR was considered a scavenger receptor, 
regulating the extracellular IGF-II concentrations, but recent studies suggest that the IGF-IIR 
also functions in signal transduction and may play an important role in tumour progression 
(El-Shewy et al., 2006,). 
To add more complexity to the system, the IGFs in circulation and in the tissues, are 
associated with a family of six high affinity IGF-binding proteins (IGFBPs) that regulate the 
bioavailability of the IGFs (Baxter, 2000). The IGFBPs regulate the interaction of IGFs with 
the receptors. In human about 80% of circulating IGF-I is carried by IGFBP-3/acid label 
subunit complex (Lewitt et., 1994). All IGFBPs inhibit IGF action by sequestering IGFs and 
some IGFBPs (IGFBP-1, -3, -5) can also potentiate IGF action. The resulting change in the 
ratio of IGF to IGFBP modulates IGF/IGFBP/IGF receptor interactions and may play a role 
in normal and abnormal tissue proliferation (Mohan & Baylink, 2002).  
Overexpression of growth factors and/or their receptors is a common event in malignancy 
and provides the underlying mechanism for uncontrolled proliferation, one of the hallmarks 
of cancer (Hanahan & Weinberg, 2000). The IGF signalling system network is tightly 
controlled under normal physiological conditions and alterations that disrupt the delicate 
balance of the system can trigger a number of molecular events that can lead to malignancy. 
Many studies have involved the IGF system in carcinogenesis and tumour progression of 
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different cell types (LeRoith & Roberts, 2003). Many cancers have been shown to 
overexpress the IGF-I receptor and/or the ligands (IGF-I and IGF-II) and some combinations 
of the six IGF binding proteins (IGFBPs) (Samani et al., 2007). It appears that abnormal IGF-
IR activation can result in oncogene activation leading to increased cellular proliferation and 
malignancy. Although the IGFs are not in themselves tumorigenic factors, it has been shown 
that overexpression of IGF-II, as in the case of loss of imprinting (LOI) (Pavelic et al, 2002), 
can contribute to gynaecological malignancies like ovarian cancer (Murphy et al., 2006) and 
choriocarcinoma (Diaz et al., 2007).  
Compared to other types of cancer, like breast, colon, prostate, and lung, little research has 
been done on the relationship between the IGF family and cervical neoplasias, and by now, 
much remains to be learned. In this review, we will discuss some of the studies focused on 
the role of the components of the IGF system in the progression of cervical cancer and its 
potential utility as a diagnostic biomarker.  
2. The IGF system and cervical cancer 
Cervical cancer is the third most commonly diagnosed cancer and the fourth leading cause 
of cancer death in females worldwide, accounting for 9% (529,800) of the total new cancer 
cases and 8% (275,100) of the total cancer deaths among females in 2008. More than 85% of 
these cases and deaths occur in developing countries. Worldwide, the highest incidence 
rates are in Eastern, Western and Southern Africa, as well as South-Central Asia and South 
America (Jemal et al., 2011). In Colombia, cervical cancer is one of the most common causes 
of cancer mortality among women (Ferlay, 2010).  
Persistent infection with high-risk types of HPV (HR HPV) has been identified as the main 
risk factor for the development of cervical cancer and its precursor lesions, squamous 
intraepithelial lesions (SIL) (Walboomers et al., 1999; Muñoz et al., 2003). SILs precede the 
development of cervical cancer and are classified in two groups: low-grade SIL (LSIL), and 
high-grade SIL (HSIL) (Solomon et al., 2002) (Fig. 2). Although HPV infections are among 
the most frequent sexually transmitted diseases, infections are usually self-limited and 
revert spontaneously, with only a small group of women developing cervical cancer 
(Woodman et al., 2001). The evolution of infection to LSIL, HSIL and cancer is dependent on 
several factors, many of which remain to be identified. Despite intensive investigation, the 
tumor biology of this disease is still largely unknown. Although prognostic factors such as 
pelvic lymph node metastasis affects the outcome of cervical cancer, the variability in 
progression-free and overall survival (OS) among patients with similar clinical and 
pathological characteristics, makes it difficult to predict the outcome reliably (Huang et al., 
2008). Current research strives to determine why certain HPV-positive women develop 
cervical cancer while others do not (Schaffer et al., 2007).  
2.1 Serum levels of IGFs as cervical cancer biomarkers 
IGF-I is a potent mitogenic growth factor that plays a critical role during embryogenesis and 
development in human and animal species. Together with Growth Hormone (GH) 
constitute an axis that regulate postnatal growth and development in an endocrine, 
paracrine and autocrine mode of action. IGF-I is produced by numerous adult organs, with 
major contribution of liver to overall circulating IGF-I levels. After puberty, circulating IGF-I  
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Fig. 2. Schematic representation of cervical cancer and its precursor lesions. Low-grade 
squamous intraepithelial lesions (LSIL), High-grade squamous intraepithelial lesions 
(HSIL). 
levels decline, in contrast to IGF-II levels that remain elevated throughout adult life (Bang & 
Hall, 1992).  
The proliferative and anti-apoptotic effects of IGF-I observed in animal and cell cultures, 
made it an obvious risk factor candidate in cancer development. In attempt to find a reliable 
serum biomarker to predict occurrence, progression or prognosis of human cancer, scientists 
have investigated the correlation of serum IGF-I or IGFBP-3, the most abundant IGFBP in 
circulation, to the prevalence of a variety of cancers. Prospective and retrospective studies 
have demonstrated an association between high concentrations of serum IGF-I and 
increased risk for prostate and premenopausal breast cancer (Renehan et al., 2004), whereas 
an inverse association has been reported for certain types of cancer, including gastric (Lee et 
al., 1997), endometrial (Lacey et al., 2004), liver (Stuver et al., 2000), and contradictory results 
for lung cancer (Yu et al, 1999; Mazzoccoli et al., 1999; Renehan, 2004).  
With respect to cervical cancer, results have not shown consistency. Mathur et al. found that 
serum IGF-II levels were elevated, whereas IGFBP-3 levels were decreased, across the 
cervical lesion spectrum, and proposed that this could be used as an aid for early diagnosis 
and predicting prognosis of cervical cancer (Mathur et al., 2000, 2003, 2005). Two other 
epidemiological studies (Lee et al., 2010; Wu et al., 2003) did not find an association between 
IGFBP-3 levels and risk of squamous intraepithelial lesions, but on the other hand, a strong 
significant increase in the risk of low-grade or high-grade squamous intraepithelial lesions 
was observed for women with IGF-I serum levels in the highest versus the lowest quartiles.  
We conducted a case-control study on Colombian women with SIL and cervical cancer, and 
our findings illustrated an inverse association between cervical cancer risk and IGF-I 
circulating levels. In accordance to this result, IGF-I/IGFBP-3 molar ratio was also inversely 
associated with cervical carcinoma (Serrano et al., 2006). Similar results were obtained in a 
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study conducted in patients with diagnosed pre-cancer lesions where levels of IGF-I were 
inversely associated with risk of high-grade cervical intraepithelial neoplasia (Schaffer et al, 
2007).  
A recent prospective study reported a possible influence of the IGF axis on the natural 
history of oncogenic HPV and the development of cervical neoplasia (Harris et al., 2008). A 
high IGF-I/IGFBP-3 ratio was associated with increased persistence of oncogenic HPV 
infection [adjusted hazard ratio (AHR), 0.14; 95% confidence interval (95% CI), 0.04-0.57], 
whereas IGFBP-3 was inversely associated with both the incident detection of oncogenic 
HPV (AHR, 0.35; 95%CI, 0.13-0.93) and the incidence of oncogenic HPV positive cervical 
neoplasia (that is, squamous intraepithelial lesions at risk of progression; AHR, 0.07; 95% CI, 
0.01-0.66). We conducted a case-control study with in a prospective populational-based 
cohort of 2200 women, followed-up during 10 years. Results adjusted by age, menarche, 
smoking, parity and hormonal contraceptives, showed that high IGF-I serum levels were 
associated with persistence (lower vs. higher quartile: RR 2.60 95% CI 0.61–10.94) and 
prevalent (lower vs. higher quartile: RR 2.67, 95% CI 0.37–19.09) HPV infection, however, no 
significance was achieved, and no association can be demonstrated (Serrano et al., 2010b).  
A recent nested case-control study (151 cervical cancer cases, 443 controls), found an inverse 
correlation between IGFBP-3 serum levels in pregnant women and risk of cervical cancer 
[OR 0.43 (95% CI 0.21-0.86)], suggesting that IGFBP-3 measured in pregnancy may be a 
marker of lower risk of cervical cancer (Jeffreys et al., 2011). In early-stage cervical cancer 
patients, lower IGF-I levels seemed to be associated with worse overall survival rate, but 
was not of an independent value, and there was no relationship between IGFBP-3 levels and 
survival (Huang et al., 2008).  
It is unclear why increased serum IGF-I levels may have a protective effect on development 
of cervical cancer, whereas in breast and prostate cancer it has the opposite effect. One of the 
theories is that the natural history to cervical cancer, where infection with HPV plays a 
crucial role, differs from sex hormone-related cancers (Schaffer et al., 2007). Larger 
prospective investigations are indicated to better clarify these associations, including any 
potential HPV type-specific differences in the effects of IGFs.  
2.2 Aberrant expression of IGFs in cancer 
Several lines of evidence support an important role for the IGF system in tumor tissue. IGF-
IR activation is involved in several processes associated to oncogenic transformation, such 
as proliferation, migration and invasion (Coppola et al, 1994; Pavelic et al., 2002; Samani et 
al., 2007; Sell et al., 1994). IGF-I expression rarely occurs in tumoral cells, but can be 
produced by stromal cells surrounding the tumor. IGF-II, IGF-IR and certain IGFBPs are 
overexpressed in many primary tumors and cancer cell lines (Cullen et al., 1990; Hellawell et 
al., 2002; Werner & LeRoith, 1996). IGFBP-3 generally has, with some exceptions, a rather 
inhibiting effect on IGF action in tumor tissues (LeRoith & Roberts, 2003). 
Increased expression of IGF-I, IGF-II, IGF-IR, or combinations thereof have been 
documented in various malignancies including glioblastomas, neuroblastomas, 
meningiomas, medulloblastomas, carcinomas of the breast, malignancies of the 
gastrointestinal tract, such as colorectal and pancreatic carcinomas, and ovarian cancer 
(Samani et al., 2007). These data show that whereas a correlation between IGF-I/ IGF-II 
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expression levels and tumor progression could be consistently documented in some 
malignancies (e.g., colorectal, hepatocellular, and pancreatic carcinomas), no consistent 
correlation was seen in others (e.g., breast cancer). Moreover, in some cases, conflicting 
results were obtained in different studies that analyzed the same types of cancers (e.g., 
gliomas) (Samani et al., 2007). Overexpression of IGF-II has been reported in several 
malignancies. A study identified the loss of imprinting (LOI) of the gene, frequently 
observed in the colonic mucosa of colorectal carcinoma patients, as a risk factor for 
developing colorectal carcinoma (Cui et al., 2003). Overexpression of IGF-II and IGF-IR, was 
observed in gestational trophoblastic neoplasias, including hydatidiform moles and 
choriocarcinoma, correlating with the elevated IGF-II levels in the circulation (Díaz et al., 
2007), Taken as a whole, these studies suggest that the IGFs can play a paracrine and/or 
autocrine role in promoting tumor growth. 
IGF-IR may also form hybrid receptors with one ┙- and ┚- subunit from the IR. There are 
two IR isoforms formed by alternative splicing of exon 11, IR-A which lacks exon 11 and IR-
B which contains exon 11. IGF-I and IGF-II, bind to hybrid receptors IGF-IR/IR-A leading to 
mitogenic signaling. IGF-II and insulin bind to IR-A leading also to mitogenic signaling, 
whereas, activation of IR-B by insulin, or the hybrid IGF-IR/IR-B by IGF-I, results mostly in 
metabolic signaling. After in vitro and in vivo studies demonstrating that insulin may also 
play a significant and independent role in tumorigenesis, insulin is now receiving more 
attention in this regard (Gallagher & LeRoith, 2011).  
In the past few decades, accumulating evidence has established that insulin receptors (IRs) 
are usually abnormally expressed in cancer cells, where they mediate both the metabolic 
and nonmetabolic effects of insulin. Most recently, it was observed that splicing of the IR 
gene is altered in cancer cells, thus increasing IR-A/IR-B ratio, which affects the cell 
response to circulating IGFs and insulin (Belfiore et al., 2009). As it was mentioned earlier, 
many tumors overexpress IGF-II, which also signals through the IR-A isoform. An 
important role of the IGF-II/IR-A loop has been observed in gestational trophoblastic 
diseases. Both IGF-I and IGF-II stimulated JEG-3 choriocarcinoma cell invasion, although 
they signal through different receptors: IGF-I through IGF-IR, and IGF-II through IR-A. In 
JEG-3 cells, which predominantly express IR-A, IGF-II stimulated cell invasion more 
potently than insulin (Diaz et al., 2007). The effects of IGF-II may also be mediated by the 
IGF-IIR, as reported in trophoblast cells (MacKinnon et al., 2001), giving more relevance to 
the role of this receptor in signaling and tumorigenesis. 
2.2.1 Tissue expression of IGFs as risk or prognosis biomarkers in cervical cancer 
In a recent study the expression levels and activated status of IGF-IR were measured by 
immunohistochemistry in formalin-fixed and paraffin-embedded specimens. IGF-IR levels 
and phosphorylation status were significantly high in cervical intraepithelial neoplasia (CIN 
III) and invasive cancer specimens (Kuramoto et al., 2008). An interesting retrospective 
analysis of patients with early-stage cervical cancer evaluated IGF-IR expression levels by 
immunoflorescent stain. Authors found that high-grade expression of IGF-IR, is an 
independent predictor of cervical cancer death and recurrence, and when combined with 
elevated squamous cervical cancer antigen (SCC Ag) serum level, could further help 
identify the subgroup of patients at higher death risk. Colocalisation of IGF-I and IGF-IR in 
the cancerous tissues, and the lack of correlation between circulating IGF-I or IGFBP-3, and 
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IGF-IR overexpression in cervical cancer tissue, give support to a paracrine or autocrine 
function of the IGF system in early-stage cervical cancer, with the corresponding adverse 
IGF-I stimulation of IGF-IR signaling (Huang et al., 2008).  
Only few studies have addressed the analysis of gene expression on exfoliated cells. The 
remaining cellular material after preparation of routine Pap smear can be used for the search 
of new biomarkers at both the mRNA and protein levels. The use of cervical scrapes instead 
of biopsies for biomarker studies has several advantages, since this is a noninvasive 
procedure, the material obtained is not affected by stroma or other contaminants, as is the 
case in the analysis of tissue homogenates and can be the base for molecular epidemiology 
studies.  
In a study on cervical scrapes from SIL and cancer patients, we found no difference in IGF-II 
mRNA levels between cancer and normal cells, whereas at the protein level, IGF-II 
expression was reduced in cancer cervical scrapes (Serrano et al., 2007, 2010a). There is 
ample evidence that the levels of IGF-II mRNA differ from the protein. While IGF-II 
transcripts were higher than in normal tissue in prostate cancer (Tennant et al., 1996), Wilms 
tumors (Haselbacher et al., 1987), and glioblastomas and astrocytomas (Hultberg et al., 
1993), it was not the case for the protein. High levels of IGF-II protein, but not mRNA were 
found in pheocromocytomas (Haselbacher et al., 1987). These evidences indicate that 
regulation of IGF-II expression involves transcriptional mechanisms, as genomic imprinting, 
but also post-transcriptional regulation, that can occur through malignant progression. A 
member of the IGF-II mRNA binding protein family (IMP), IMP-3, has been reported to be 
an activator of IGF-II mRNA translation and therefore may play a critical role in IGF-II-
dependent cellular proliferation (Liao et al., 2005). IMPs were detected in various cancers; 
increased levels were found in ovarian cancer and correlated with prognosis. There are no 
studies about IMP in cervical cancer. 
Few studies have examined the expression of hybrid receptors in cervical cancer cells. In a 
recent study, we found that IR-A, IR-B and hybrid receptors coexist with IGF-IR in human 
papillomavirus-positive cervical cancer cells. Tyrosine phosphorylation of the receptors and 
activation of the MAPK and PI3-K pathways were observed upon ligand binding, which 
may explain the anti-apoptotic effect mediated by IGF-I in these cells (Serrano et al., 2008). 
Further studies are required to fully understand the significance of the hybrid receptors, 
especially IGF-IR/HR-A in cervical carcinogenesis and for the design of therapies to target 
their effects.  
2.2.2 The role of IGF in radioresistance in cervical cancer 
The crucial role of IGF-IR in promoting resistance to cancer treatments, such as radiation 
and chemotherapy, is well documented for several cancer types (Samani, et al., 2007). IGF-IR 
down-regulation by antisense nucleotides or its inhibition by tyrosine kinase inhibitors 
increases cancer cell sensitivity to both radiation and chemotherapy in a variety of 
malignancies. Some studies indicate an important role of IGF-IR in several pathways 
involved in the induction of radioresistance (Belfiore et al., 2009).  
The identification of the mechanisms underlying the effects of IGF-II/IGF-IR signaling in 
the induction of resistance to oxidative stress in cancer cells may provide useful information 
for the selection of the appropriate treatment strategy. In a study with advanced cervical 
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cancer patients (CIN I-III), we found that tumor tissues co-expressing IGF-IR and IGF-II, 
showed an increase (4.6-fold) in the risk of developing resistance to radiotherapy. The 
increased expression of the glycolitic enzyme glyceraldehyde 3-phosphate dehydrogenase 
(GAPDH) in these cancer tissues, demonstrated the metabolic shift to glycolisis under 
hypoxic conditions (Moreno-Acosta et al., 2010). Therefore, targeting IGF-II/IGF-IR 
signaling may be a desirable option in the treatment of tumors overexpressing the IGF-IR.  
3. Biomarkers for cervical cancer 
Biomarkers used for screening in cancer, usually consist of biomolecules that are released 
from tumors or precancerous lesions into the bloodstream, urine, or other means, they 
should have the property to survive the metabolic degradation to be measurable (Ahlquist, 
2010). Molecular changes that occur in the development of tumors may take several years; 
some biomarkers can be used to detect early stage disease. However, biomarkers are usually 
found at relatively low level compared to other biomolecules; research and validation as 
possible diagnostic tests depend critically on the ability to achieve measurements with high 
precision and sensitivity.  
Several biologic markers or indexes have been studied as potential tools to determine the 
prognosis and biological behaviour of various types of gynaecological neoplasias. From 
years the search of cervical cancer biomarkers has been fed through different techniques, 
such as immunohistochemistry (IHC), probably the most affordable and simple technology 
to detect many such biomarkers (McCluggage, 2002; Munoz et al., 2003). This fact prompted 
investigators to develop and test antibodies in a widespread range of neoplasic lesions. In 
this approach, some researchers found a two component system, denominated MaTu, 
consisting of an exogenous transmissible MX agent (coding for p58X protein) and an 
endogenous MN (coding for MN-protein) in HeLa cells (Závada et al., 1993). The association 
between MN protein (MN-p) expression and oncogenesis was suggested by its presence in 
neoplasms, and not in benign tissue (Brewer et al., 1996; Liao et al., 1994). Because HeLa is a 
cultured human uterine cervix carcinoma cell line, these authors concluded that MN-p had 
great use as a tumour marker in the evaluation of cervical carcinoma and could predict 
progression in precursor cervical intraepithelial neoplasic (CIN) lesions. Nonetheless, its 
utility was questioned as MN-p inmunostaining was not limited to neoplastic tissue, but 
found in adjacent basal cell hyperplasia, metaplasias and benign glandular epithelium (Liao 
et al., 1994; Resnick et al., 1996).  
Ki67, a nuclear proliferation associated antigen is expressed in the growth and synthesis 
phases of the cell cycle (G1, S, G2, and mitosis) but not in the resting phase, G0. The 
proportion of cells which express Ki67 (Ki67 index) is an excellent measure of neoplasm 
proliferation. Production of specific antibodies against recombinant DNA Ki67 antigen 
(MIB-1) confirmed the definite use of MIB-I immunoreactivity, exhibiting close correlation 
with CIN grade and providing additional risk prediction beyond HPV type (Resnick et al., 
1996). In low-grade CIN, anti-MIB-1 staining is not detected in superficial levels of 
epithelium, whereas in high-grade CIN full thickness staining is present. The authors´ 
hypothesis was that viral gene expression undergoes programmed cessation in superficial 
layers of low-grade CIN; therefore viral E6/E7 protein is no longer present to inhibit p53 
and the cells stop cycling (so Ki67 detection through anti-MIB-1 disappears). In high-grade 
CIN, viral expression of E6/E7 proceeds unabated often in absence of vegetative viral 
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functions leading to inhibition of p53 and uninhibited cell cycling (so Ki67 detection through 
anti-MIB-1 continues). In contrast with MN-p expression, anti-MIB-1 shows consistent 
results by most investigators and exhibits definitive, important associations with clinical 
outcome and basic carcinogenesis hypotheses in the uterine cervix (Costa, 1996). 
For several years, it has been known that high vascularity is characteristic of grade 3 CIN 
and invasive lesions, and angiogenesis has been associated as indicator of prognosis. The 
onset of angiogenesis in human cervical cancer occurring during the premalignant 
dysplastic stage is unique. An association between lymphatic high microvessel density with 
vascular invasion and a lower global survival rate has been described. There is a study 
demonstrating that microvessel density in carcinomas of the uterine cervix is a factor 
associated with poor prognosis (Tjalma et al., 1999). The authors showed that during the 
progression from noninvasive to microinvasive cervical carcinoma, the microvessel density 
increases significantly. However, the vessel density does not predict recurrence of 
noninvasive lesions. Once the tumour cells have passed the basal membrane, the tumour 
apparently switches to an angiogenic phenotype. Angiogenesis becomes a tumour initiator 
with prognostic potential (Tjalma et al., 1999). Measures of factor VIII, CD31, and vimentin, 
showed no association between microvessel count and lymph node invasion, depth of 
invasion, and histological differentiation. Nevertheless, these studies found an association 
between lymphatic vessel invasion and a larger number of newly formed vessels (Di Leo et 
al., 1998).  
Other studies have proposed anti-CD34 as a marker for evaluating angiogenesis in cervical 
cancer (Vieira et al., 2004, 2005). Anti-CD34 antibody is a highly sensitive marker for 
endothelial cell differentiation and has also been studied as a marker for vascular tumours 
(Stross et al., 1989; Traweek et al., 1991). Vieira et al. (Vieira et al., 2005) showed that this 
antibody was able to detect a number of microvessels on neoplasm of the uterine cervix 
better than anti-factor VIII. They suggested that anti-CD34 antibody reactivity in cervical 
carcinoma is associated with pathoanatomical features, as microvessel density or invasion, 
indicative of poorer prognosis and greater risk of recurrence (Vieira et al., 2005). Briefly, 
they showed lymphatic invasion in 40% of the cases, while vascular and perineural invasion 
was observed in 24% and 19% of the cases, in a population of 62 patients diagnosed with 
invasive cervical carcinoma, stages Ib and IIa. They also observed that 55% of women whose 
carcinoma presented high microvessel density had an undifferentiated type of cancer, 
suggesting that the presence of lymphatic invasion may associate with higher microvessel 
density. In general, different markers for angiogenesis may or may not present a statistically 
significant association with different pathoanatomic features of cervical cancer. These 
possible markers should be tested prospectively as a prognostic and predictive factor of the 
response to different therapies used in cervical carcinoma.  
On the other hand, a recent study explored the power of serum markers such as squamous 
cell carcinoma antigen (SCC), CYFRA 21-1, CA 125, immunosuppressive acidic protein 
(IAP) and vascular endothelial growth factor (VEGF) in patients with cervical cancer 
(Gadducci et al., 2008). Squamous cell carcinoma antigen comprises two similar proteins, 
SCC-1 and SCC-2, that posses protease inhibitory property: SCC-1 inhibits chymotrypsin 
and cathepsin L, while SCC-2 inhibits cathepsin G and mast cell chymase. Both proteins 
exert anti-apoptotic effects. The mechanism of protection of tumour cells from apoptosis 
involves the inhibition of caspase-3 activity and/or upstream proteases. SCC-1 and SCC-2 
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reside in the citosol of squamous cells, and their presence in the sera of patients with 
advanced squamous cell carcinomas is mainly due to a passive release rather than an active 
secretory process into the circulation. Increased SCC levels have been observed in 28-88% of 
patients with squamous cell cervical cancer. Pre-treatment SCC levels reflect tumour stage 
and size, cervical stoma invasion, lymph-vascular space status, parametrial involvement 
and lymph node status; however, its clinical relevance is still debated. 
CA 125, an antigenic determinant of a high molecular weight glycoprotein, is recognized by 
a monoclonal antibody developed against a human ovarian cancer cell line. Elevated CA 125 
levels are detectable in 20-75% of patients with cervical adenocarcinoma and have been 
associated with advanced tumour stage, large tumour size, high histological grade, lymph 
node involvement and status. CA 125 is detected in normal adult fallopian tube, 
endometrium, endocervix and peritoneum, and in vitro studies showed that CA 125 
secretion by human mesothelial cell monolayers may be enhanced by the inflammatory 
cytokines interleukin-1 and tumour necrosis factor. However, the specificity of the antigen is 
not yet optimal, since elevated serum CA 125 can be found in benign gynaecological 
conditions, such as endometriosis and pelvic inflammatory disease, benign non-
gynaecological conditions, such as hepatitis, pancreatitis, renal failure and pleural effusion 
and non-gynaecological malignancies, including lung cancer, pancreatic cancer and non-
Hodgkin’s lymphoma. 
Serum levels of vascular endothelial factor (VEGF) are often elevated in patients with 
cervical cancer, and decrease significantly after successful treatment. However, the clinical 
relevance of serum VEGF is still investigational (Gadducci et al., 2008). 
New predictive biomarkers for cervical cancer are still necessary to improve the accuracy of 
screening and thereby reduce overtreatment and possibly improve cost-effectiveness of the 
treatment. Advances in molecular biology and high throughput technologies have heralded 
a new era in identification of biomarkers and molecular targets related to carcinogenesis to 
improve our understanding of the disease and will facilitate screening, early detection, 
management, and individualized targeted therapy. 
3.1 Proteomic studies 
Proteomics has emerged as a promising tool for unravelling protein signatures that are 
associated with a particular malignancy that can be useful biomarkers of the disease. High-
throughput technologies like surface-enhanced laser desorption and ionization-time of flight 
mass spectrometry (SELDI-TOF MS), nanoHPLC-MS/MS or the combination of one- or two-
dimensional gel electrophoresis (1-DE, 2-DE) methods with multidimensional 
chromatographic separation and MS provide a snapshot of the proteome. Validated protein 
biomarkers could be useful in early detection of disease, monitoring disease progression or 
monitoring response to treatment.  
3.1.1 Proteomic studies on body fluids 
After exploring markers in tissue, several studies have focused on biomarker discovery in 
body fluids which would be advantageous for eventual clinical implementation. Cervical 
mucous or cervical vaginal fluid (CVF) is potentially an ideal sample to screen for 
biomarkers for early detection of cervical cancer. As cervical mucous is produced in the 
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microenvironment where cervical neoplasia arises, it is likely to include proteins produced 
by the lesion as well as by the host in response to the lesion. Several studies have analyzed 
peptides and proteins present in human cervical mucous (Dasari et al., 2007; Pereira et al., 
2007; Tang et al., 2007). A recent study identified 151 new proteins that included proteins 
present in the lower female genital tract, such as HBD-2 and cathelicidin, two proteins that 
play an important role in the innate immunity of the cervicovagina (Zegels et al., 2009). 
Another recent study on cervical mucous proteome indicated that plasma proteins were 
abundant in cervical mucous (Panicker et al., 2010). The majority of proteins identified were 
categorized under metabolism and immune-response functional groups.  
In contrast to plasma samples, some authors discuss the advantages of cervical mucous as a 
potential source of concentrated biomarkers due to lesser dilution of the sample in CVF-
vaginal washings (volume ±50 mL) in comparison to plasma volume (±3 L) (Good et al., 
2007). In addition, altered biomarker expression patterns in plasma are often not very 
specific, as they may be associated with different pathologies, because plasma comes in 
contact with all organs of the body. In contrast, when using CVF samples, it is expected that 
expression patterns will directly correlate with gynaecological pathologies (Zegels et al., 
2009). However, it should be taken into account that CVF is a body fluid that can be highly 
influenced by many biological factors including menstruation, age, infection, sexual 
intercourse, usage of contraceptives, pregnancy, etc. Moreover, conditions of CVF collection 
and the experimental proteomic strategy could affect the proteome results. Although there 
are promising results, studies in biomarkers in body fluids have not reached consensus on 
peptides or proteins that have this feature. 
3.1.2 Membrane proteomic studies 
The main potential of proteomics in cancer research is not only derived from individual 
experiments, but from comparative studies between different types and states of cancer. 
There is a need to integrate proteomics, genomics and metabolomics with the aim of 
achieving a functional and comprehensive interpretation of clinical and pathological data. 
Comparative proteomic studies have provided tools for establishing some molecular 
mechanisms of cancer progression, either from normal to neoplasic cells, or from cancer 
models with different malignant phenotypes. Information obtained through proteomic 
analysis allows building extensive and comprehensive databases leading to discovery of 
tumor biomarkers. 
Metastasis represents the main cause of death in cancer patients; this multi–step process 
involves the acquisition of migrating and invasive phenotypes, where the plasma membrane 
displays a fundamental role. Membrane proteomic studies constitute an analytical challenge 
due to its heterogeneous composition, dynamic physicochemical characteristics and 
hydrophobicity; however, 60% of therapeutic targets are directed against membrane 
proteins. The study of well established cancer cell lines with different phenotypes allows the 
correlation between the IGF axis expression/activation with membrane protein expression 
measurements. In particular, cellular motility depends on the adaptive response to 
environment that extensively relies on key molecular elements of the plasma membrane and 
cytoskeleton, and therefore usually considered as tumour targets.  
Here we present novel results of studies on membrane proteomes of cervical cancer cell 
lines, differing in viral status and invasive phenotypes: HeLa, an invasive HPV positive cell 
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line, and C33-A, a non-invasive HPV negative cell line (Garay et al., 2010). C33-A cells 
express almost exclusively IR-A while HeLa express IGF-IR, IR-A and IR-B. Functional 
assays showed that IGF-I and IGF-II stimulate migration and invasion in HeLa but not in 
C33-A cervical cancer cells. In order to make comparisons between proteomic maps, we 
obtained proteomic maps of the two cell lines by two–dimensional electrophoresis (2-DE), 
and used the PDQuest (Bio-Rad®) and Progenesis SameSpot (Nonlinear Dynamics Ltd) 
softwares, to perform between-gel spot comparisons (Fig. 3 A,B). A total of 641 spots in C33-
A and 493 spots in HeLa proteomes were identified, with 399 spots matching between the 
two cell lines. This means that the whole proteomic profiles of cervical adenocarcinoma and 
cervical carcinoma cells share 80% of similarity, suggesting that the differences in 
occurrence, prognosis, dissemination and recurrence after treatment, may be related to a 
limited number of proteins and their relative distribution and expression.  
 
A. B.
C. D.
215
M.W. (kDa)
120
84,0
60,0
39,2
28,0
18,3
pH 3 pH 10
215
M.W. (kDa)
120
84,0
60,0
39,2
28,0
18,3
pH 3 pH 10
M.W. (kDa)
205
M.W. (kDa)
66,0
55,0
30,0
21,0
14,0
6,5
45,0
80,0
97,0
116
205
66,0
55,0
80,0
97,0
116
45,0
30,0
21,0
14,0
6,5
pH 3 pH 10 pH 3 pH 10
 
Fig. 3. Proteomes and sub-proteomes of cervical cancer cells. Whole protein extracts from 
HeLa (A) and C33-A (B) and enriched membrane extracts from HeLa (C) and C33-A (D) 
were separated by two-dimensional electrophoresis (2-DE) on IPG NL strips pH 3-10 
followed by SDS-PAGE and stained with colloidal Coomassie Blue.  
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Frequently, whole proteomic profiles do not represent the complete map of the expressed 
proteins in a cell at a given moment; the concentration of some proteins can mask others less 
abundant but with pivotal biological roles. Study of sub-cellular compartments could 
improve the identification of a higher number of proteins and consequently a more efficient 
detection of therapeutic targets. We obtained enriched protein membrane extracts from 
HeLa and C33-A cells by cell surface biotin labelling followed by avidin purification and 
separation by 2-DE to obtain the corresponding membrane proteomes (Fig. 3 C, D).  
We detected 351 spots in HeLa sub-proteome, out of which 207 spots (41%) were present in 
the whole proteome and 144 spots corresponded to new proteins not visualized in the total 
proteome. With respect to C33-A, 395 spots were found in the membrane proteome where 
170 spots (43%) matched with the total proteome; additionally 255 new spots were detected. 
Furthermore, comparison of membrane-enriched proteomes, showed a 58% match between 
the two cell lines with 272 common proteins, out of which, 86 proteins were found to be 
differentially expressed (>3-fold). The invasive abilities of HeLa in opposition to C33-A cells, 
may be related to the observed differences in the membrane protein profile. 
In order to identify a higher number of proteins and overcome the limitations associated 
with the separation of membrane proteins by bi-dimensional electrophoresis, we conducted 
a multidimensional analysis of enriched membrane fractions. Proteins were separated by 
SDS-PAGE, each lane in the gel was cut and divided in equal fragments and digested with 
trypsin. The peptides were separated by reversed-phase liquid chromatography (LC) and 
analyzed in a hybrid quadrupole mass spectrometer–time of flight (Q-TOF) instrument. 
Bioinformatics analysis was performed using Mascot Distiler® and Proteome Software 
Scaffold, which allowed the identification of 44 and 56 proteins in HeLa and C33-A 
fractions, respectively.  
Results showed a differential or exclusive protein expression profile that correlated with cell 
phenotype. We identified 33 proteins exclusively expressed in C33-A cells that 
corresponded to cell cycle regulation, metabolism, stress response and immune system 
evasion, more related to a proliferative non-invasive phenotype. Meanwhile, 22 proteins 
exclusively expressed in HeLa cells, where mainly involved in cytoskeleton remodelling and 
associated with cell motility, according to the invasive phenotype. Among the new 
identified proteins, the more relevant in the regulation of metastatic properties, include: 
Filamin A and B, Myoferlin and the CD44 - Moesin complex, which have been previously 
associated with cell adhesion and tumour progression (Feng & Walsh, 2004; Ravid et al., 
2008; Bernatchez et al., 2007). 
To explore the relationships between the identified proteins and the IGF system, we used 
the STRING 8.3 database to examine the known or predicted protein-protein interactions 
among them. The interaction network was built including all the previously identified 
proteins in the membrane proteome and the members of the IGF system. The interaction 
network obtained for HeLa cells is visualized in Fig. 4. This analysis confirmed the 
interaction of some components of the membrane with members of the IGF family, and 
suggests a potential role in the promotion of the invasive phenotype display by these cells. 
In particular, this analysis confirmed a direct interaction between IGFBP-3 and the CD44 - 
Moesin complex, associated with cell adhesion and tumor progression, meaning a 
promising target for cervical cancer invasion and metastasis control. In conclusion, our  
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Fig. 4. Protein-protein interaction network representing the associations between the IGF 
system and identified membrane proteins expressed by the cervical cancer HeLa cell line. 
The network is visualized by STRING 8.3 database. Each circle represents an individual 
protein with the recognized abbreviated name. Connecting lines represent association.  
approach is unique as it considers the IGF receptors in a wider context within a protein 
network, and shows that the membrane is a rich reservoir for potential targets for cancer.  
4. Conclusion 
The evidence reviewed above shows that the IGF system plays a central role in many 
aspects of the development and progression of cervical cancer. The effects of components of 
the IGF axis in cervical carcinogenesis share some similarities with those observed in other 
types of cancer, however, clear differences exist that reflect specificities, possibly due to 
associations with oncogenic and nononcogenic HPV. The available data support 
dysregulation of the IGF system expression and signaling, that could promote the 
progression to a malignant phenotype. It is plausible to consider these molecules as 
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promising targets for cervical cancer invasion and metastasis control and source of valuable 
biomarkers of the disease, as deduced from the proteomic approach of membrane targets. 
Advances in molecular biology and high throughput technologies will improve our 
understanding of the disease and the search for reliable biomarkers that will facilitate 
screening, early detection, management, and individualized targeted therapy. 
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